ADMA Biologics (ADMA)

ADMA’s core business is built around immune globulin products, including intravenous immune globulin therapies used to support patients whose immune systems cannot produce sufficient antibodies. These products are made from human plasma and require complex collection, testing, fractionation, purification, and fill-finish processes. The company also produces and sells plasma-derived intermediate fractions generated during its approved manufacturing operations, and it may provide contract services such as laboratory work, filling, labelling, and packaging for third parties.

The company reports activities across bio-manufacturing, plasma collection centres, and corporate functions, with bio-manufacturing representing the primary revenue contributor. Its commercial focus is largely in the United States, where demand for immune globulin therapies has been supported by diagnosis of primary immunodeficiency diseases, broader medical use of plasma-derived products, and the need for dependable domestic supply.

For investors, ADMA offers exposure to the specialty biologics and plasma therapeutics market rather than traditional small-molecule drug development. Its performance depends on manufacturing execution, plasma supply, regulatory standards, reimbursement dynamics, physician adoption, and the ability to expand production efficiently. The company’s distinctive position lies in combining commercial plasma-derived products with internal collection and manufacturing capabilities in a highly regulated healthcare niche.